GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M

GeneDx Holdings Corp.

2024-Q2 EPS reported -$1.88 revenue$132,936,000

Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).
Adjusted gross margin from continuing ops 62% (up from 37% YoY).
Adjusted net loss narrowed to $2.7M, an improvement of 93% YoY.
GAAP net loss $29.2M including $13M one-time litigation charge.
Raises FY2024 revenue guidance to $255-265M; reiterates path to profitability in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.